Literature DB >> 34788131

Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases.

Cheng Ye1, Hiroshi Yano1,2, Creg J Workman1, Dario A A Vignali1,3,4.   

Abstract

The balance between inflammatory and anti-inflammatory immune responses is maintained through immunoregulatory cell populations and immunosuppressive cytokines. Interleukin-35 (IL-35), an inhibitory cytokine that belongs to the IL-12 family, is capable of potently suppressing T cell proliferation and inducing IL-35-producing induced regulatory T cells (iTr35) to limit inflammatory responses. Over the past decade, a growing number of studies have indicated that IL-35 plays an important role in controlling immune-related disorders, including autoimmune diseases, infectious diseases, and cancer. In this review, we summarize the current knowledge about the biology of IL-35 and its contribution in different diseases, and we discuss the potential of and barriers to harnessing IL-35 as a clinical biomarker or immunotherapy.

Entities:  

Keywords:  IL-35; autoimmune diseases; cancer; infection

Mesh:

Substances:

Year:  2021        PMID: 34788131      PMCID: PMC8820099          DOI: 10.1089/jir.2021.0147

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  145 in total

1.  A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins.

Authors:  Julia Diegelmann; Torsten Olszak; Burkhard Göke; Richard S Blumberg; Stephan Brand
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  Assembly-induced folding regulates interleukin 12 biogenesis and secretion.

Authors:  Susanne Reitberger; Pascal Haimerl; Isabel Aschenbrenner; Julia Esser-von Bieren; Matthias J Feige
Journal:  J Biol Chem       Date:  2017-03-21       Impact factor: 5.157

3.  Aberrant IL-35 levels in patients with primary Sjogren's syndrome.

Authors:  Jie Guo; Mingli Gu; Weiwei Zhang; Yun Liu; Cheng Qian; Ammei Deng
Journal:  Scand J Immunol       Date:  2018-11       Impact factor: 3.487

4.  Low Serum Levels of Interleukin 35 in Patients with Rheumatoid Arthritis.

Authors:  Xingwang Ning; Zijuan Jian; Wei Wang
Journal:  Tohoku J Exp Med       Date:  2015-10       Impact factor: 1.848

5.  Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis.

Authors:  Qiang Xie; Wang-Dong Xu; Min Pan; You-Yu Lan; Xiao-Yan Liu; Lin-Chong Su; An-Fang Huang
Journal:  Int Immunopharmacol       Date:  2020-12-08       Impact factor: 4.932

6.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

7.  Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation.

Authors:  B-H Yang; S Hagemann; P Mamareli; U Lauer; U Hoffmann; M Beckstette; L Föhse; I Prinz; J Pezoldt; S Suerbaum; T Sparwasser; A Hamann; S Floess; J Huehn; M Lochner
Journal:  Mucosal Immunol       Date:  2015-08-26       Impact factor: 7.313

8.  Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner.

Authors:  Lauren W Collison; Meenu R Pillai; Vandana Chaturvedi; Dario A A Vignali
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 9.  Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.

Authors:  Andrés A Herrada; Noelia Escobedo; Mirentxu Iruretagoyena; Rodrigo A Valenzuela; Paula I Burgos; Loreto Cuitino; Carolina Llanos
Journal:  Front Immunol       Date:  2019-04-15       Impact factor: 7.561

10.  Cellular immunological changes in patients with LADA are a mixture of those seen in patients with type 1 and type 2 diabetes.

Authors:  K Singh; M Martinell; Z Luo; D Espes; J Stålhammar; S Sandler; P-O Carlsson
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

View more
  2 in total

1.  At Embryo Implantation Site IL-35 Secreted by Trophoblast, Polarizing T Cells towards IL-35+ IL-10+ IL-4+ Th2-Type Cells, Could Favour Fetal Allograft Tolerance and Pregnancy Success.

Authors:  Letizia Lombardelli; Federica Logiodice; Ornela Kullolli; Herman Haller; Chiara Agostinis; Roberta Bulla; Daniel Rukavina; Marie-Pierre Piccinni
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 2.  Recombinant BCG to Enhance Its Immunomodulatory Activities.

Authors:  Magdalena Kowalewicz-Kulbat; Camille Locht
Journal:  Vaccines (Basel)       Date:  2022-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.